injectable glp-1 agonists GLP-1s How GLP-1 medications are transforming

Learn about the Ozempic blindness lawsuit, including NAION and other vision problems, and read about the study linking semaglutide use to severe eye problems.

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

They now cost about Rs 1,0002,500 a month, and there's growing evidence pointing to benefits well beyond weight loss, including cardiovascular, metabolic, and liver health

Suggested Caption: What are you hearing about GLP-1 drugs like Ozempic, Wegovy or Mounjaro

: 1,800/month Earlier, it was 8,80010,000/month